Navigation Links
Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
Date:1/24/2010

aring alternative to oxaliplatin for the first-line treatment of metastatic CRC in 101 patients who had not received prior chemotherapy.  The trial's primary objective was to measure the relative incidence and severity of neuropathy in the FOLPI regimen compared to the FOLFOX regimen.  In addition, the study measured comparative safety and efficacy (assessed by disease control, progression-free survival (PFS) and overall survival (OS)) data; however, the study was not powered to assess the statistical significance of these secondary endpoints.  The final Phase 2 data indicated that:

  • FOLPI is associated with a statistically significant reduction in neurotoxicity compared to FOLFOX (HR <0.30; p <0.004).  Neuropathy, regardless of Grade, was 26 percent in FOLPI-treated patients and 62 percent in FOLFOX-treated patients. No Grade 3/4 neuropathy was observed with FOLPI.
  • FOLPI had similar efficacy to FOLFOX as measured by:
    • Disease Control of 75 percent and 76 percent for FOLPI and FOLFOX, respectively; (Relative risk 1.02 (95 percent Confidence Interval (CI) 0.79-1.32), p=0.9)
    • PFS of 6.8 months and 7.0 months for FOLPI and FOLFOX, respectively: HR 0.95 (95 percent CI 0.63-1.45), p=0.82
    • OS of 13.6 months and 15.6 months for FOLPI and FOLFOX, respectively: HR 1.17 (95 percent CI 0.72-1.91), p=0.53
  • Six-month and one-year survival rates were 80 percent and 52 percent for FOLPI and 83 percent and 55 percent for FOLFOX, respectively.
  • More patients who discontinued FOLFOX had associated neuropathy; neurotoxicity was not dose-limiting for FOLPI.  More patients who discontinued FOLPI had associated hematological events than with FOLFOX.
  • No hypersensitivity, cardiac or nephrotoxicity was observed with FOLPI or FOLFOX.
  • FOLPI had more frequent and severe, but manageable, thrombocytopenia an
    '/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)...  The U.S. Food and Drug Administration,s (FDA) ... biosimilar product approved in the United ... the contract manufacturing organization (CMO) industry, according to ... to the production of small-molecular drugs and lacks ... healthcare market research publisher,s report, Biopharmaceutical and ...
(Date:5/22/2015)... 22, 2015  The Mesothelioma Victims Center is ... mesothelioma get the best possible compensation, and they are ... this rare cancer caused by exposure to asbestos ... related to treatment options such as a recent ... Mesothelioma Victims Center anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
(Date:5/22/2015)... May 22, 2015   InspireMD, Inc. (NYSE MKT: ... protection systems ("EPS"), today announced that its CGuard TM ... principle investigator Prof. Piotr Musialek , at the ... Paris, France . PARADIGM, an investigator-initiated ... c A roti D revascularization I n symptomatic ...
Breaking Medicine Technology:Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
(Date:5/25/2015)... 25, 2015 After the sensational buzz ... science-based human wellness company Trivedi Master Wellness™ ... their world-class series titled, “Consciousness is Power.” Presently, the ... 13, 2015 at the routinely allotted time from 10:00pm ... will be made available to the public and accessible ...
(Date:5/24/2015)... NY (PRWEB) May 24, 2015 The ... Sunday, May 24th in San Diego at Petco Park. ... North America. On May 20th, they had a warmup ... At their preview show in Los Angeles, this beloved band ... they also played fan favorites such as "Jumping Jack Flash," ...
(Date:5/24/2015)... NH (PRWEB) May 24, 2015 ... leather, launches “InkGard™ Plus” – a classic, rugged ... the polymer allowing difficult stains, including ink, to ... 16 different colors suitable for corporate, healthcare, hospitality ... in line with EnviroLeather’s goal of developing products ...
(Date:5/24/2015)... Geneva, WI (PRWEB) May 24, 2015 ... Mercy Health System CEO - ... principal and honored at the fourth ... held April 15 at Geneva National ... (by school): ,     -Badger High School, ...
(Date:5/23/2015)... With the implementation of the Affordable Care ... difficult to provide their employees with a viable healthcare ... for employees stand to face strict penalties. Never before ... of a business’s success or failure. In an effort ... Doctors has created a varying level of less expensive ...
Breaking Medicine News(10 mins):Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 3Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3
... WASHINGTON, Feb. 5 Following is a statement,by Daniel ... his last budget, the president had an opportunity to ... nation,s No. 1 killer,and costliest disease. Instead, his proposal ... cure. We,re making steady progress in combating heart,disease and ...
... precisely which bugs in the gut are involved in which ... bugs living in seven members of the same Chinese family. ... and trillions live symbiotically inside the human body. Different people ... them. , The makeup of each persons gut microflora ...
... West Pharmaceutical,Services, Inc. (NYSE: WST ) today ... Executive Officer, and William Federici, Chief,Financial Officer, will be ... 3:00 p.m. on February 11, 2008 in New York ... will be posted on the,investor link of the Company,s ...
... Compliance Corp. (OTC,Bulletin Board: SCOM) ("Sharps" or the ... small quantity generators of medical,waste, today announced that ... Officer, will present at the RedChip Small-Cap Investor,Conference ... approximately,10:10 a.m. MST (12:10 p.m. EST) on Thursday, ...
... LAKE FOREST, Ill., Feb. 5 BIOSAFE Laboratories, ... and Glycemion, the,United States distributor, have announced the ... use in schools to help identify diabetic and,pre-diabetic ... a two-part process comprised of an immediate fasting ...
... Rapid Growth, WAYNE, Pa., Feb. 5 ... communications,platform specifically designed for the biomedical research community,announced ... of myBW (or myBioWizard), a,unique personalization tool available ... now provides biomedical researchers access to approximately,half a ...
Cached Medicine News:Health News:Statement by Daniel W. Jones, M.D., American Heart Association President on President Bush's FY 2009 Budget Proposal 2Health News:Bug guts map brings scientists closer to understanding different bugs' role in the body 2Health News:Bug guts map brings scientists closer to understanding different bugs' role in the body 3Health News:West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference 2Health News:Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona 2Health News:BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessment Kits to U.S. School Children 2Health News:BioWizard Offers Conference Abstracts with the Launch of myBW 2Health News:BioWizard Offers Conference Abstracts with the Launch of myBW 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: